8月18日，沪深两融数据显示，联影医疗获融资买入额0.58亿元，居两市第574位，当日融资偿还额0.63 亿元，净卖出554.20万元。 融券方面，当日融券卖出0.52万股，净卖出0.35万股。 来源：金融界 最近三个交易日，14日-18日，联影医疗分别获融资买入0.62亿元、0.48亿元、0.58亿元。 ...

Summary of the Conference Call for 联影医疗 Company Overview - 联影医疗 specializes in a wide range of medical imaging equipment including MRI, CT, X-ray, PET-CT, PET-MRI, and radiation therapy devices, with a growing market share and active expansion into overseas markets such as Japan, Europe, and the United States [2][3] Core Insights and Arguments - **R&D Investment**: The company places a high emphasis on R&D, focusing on the self-development of core components like MRI magnets and CT tubes to reduce costs and enhance product competitiveness, achieving full-process coverage from core parts to complete machines [2][4][5] - **Market Growth**: Since 2018, the company has maintained rapid growth, with a significant boost in 2020 due to increased demand for CT during the pandemic. Although there was a decline in 2022 and 2023, profitability is expected to rise again by 2025 [2][6] - **Chinese Medical Equipment Market**: The market size reached 53.7 billion yuan in 2020, growing at approximately 10% annually. Factors such as aging population and equipment renewal policies are expected to drive market expansion [2][7] - **Domestic Market Performance**: The company holds about 11.8% market share in China, benefiting from increasing localization rates and supportive equipment renewal policies [10] Industry Trends - **Localization Rate**: The localization rate in China's medical equipment sector is currently low but on the rise. For instance, the localization rate in X-ray is relatively high, while high-end CT components are nearing commercialization. The market share of domestic brands in MRI has reached 20% [8] - **Funding Sources**: Most funding for medical equipment procurement comes from government bonds, alleviating financial pressure on hospitals and promoting short-term purchasing demand [7] International Expansion Strategy - **Global Presence**: The company has entered over 70 countries and established multiple subsidiaries and R&D centers, employing a "one core, multiple wings" strategy to tailor product lines for different markets [11][12] - **North America and Europe**: In North America, the company has achieved coverage in over 50% of state-level administrative regions since its entry in 2013. In Europe, it aims for significant growth from 2025 to 2026, following the establishment of a subsidiary in Poland [12][15] Challenges and Innovations - **Emerging Markets**: The company collaborates with local distributors in emerging markets to enhance its presence, achieving notable success in India with a leading market share in PET CT [13] - **Industry-Academia Collaboration**: The company emphasizes collaboration with universities for scientific research, which helps in product innovation and understanding clinical needs [14] Future Outlook - **Growth Prospects**: In the short to medium term, the company is expected to continue benefiting from domestic equipment renewal demands while enhancing localization. The international strategy will focus on local market adaptation, particularly in Europe, where significant growth is anticipated [15]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗器械板块主力资金净流出6.22亿元，游资资金净流入8454.45万元，散户资 金净流入5.38亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300049 | 福瑞股份 | 1.46 Z | 11.88% | -1.05 Z | -8.52% | -4138.97万 | -3.36% | | 300003 | 乐普医疗 | 1.21 Z | 7.97% | -5108.00万 | -3.37% | -6962.47万 | -4.59% | | 600645 | 中源协和 | 9348.49万 | 9.75% | -3949.64万 | -4.12% | -5398.85万 | -5.63% | | 688271 | 联影医疗 | ...

国金证券对浩瀚深度控股股东、实际控制人一致行动协议到期不再续签暨权益变动事项核查。2013年12 月张跃和雷振明签署《一致行动人协议》及《补充协议》，2025年8月18日到期后不再续签，一致行动 关系19日起解除。 ...

Group 1 - The A-share market experienced a strong upward trend on August 18, with the Shanghai Composite Index reaching a nearly 10-year high [1] - The STAR Market Composite Index ETF by Huatai-PB rose by 1.94%, indicating positive market sentiment [1] - The STAR Market Composite Index itself surged by 2.08%, with notable gains from constituent stocks such as Nanxin Pharmaceutical and Shunlian Bio, both increasing by over 20% [1] Group 2 - As of August 18, 2025, the top ten constituent stocks of the STAR Market ETF include companies like Saiwei Technology and Haiguang Information, with varying performance in terms of price changes and trading volumes [2] - The semiconductor industry in China saw a total investment of 455 billion yuan in the first half of 2025, reflecting a 9.8% year-on-year decline, while semiconductor equipment investment grew by 53.4%, highlighting a strategic focus on supply chain autonomy [3] - Major global tech companies are significantly increasing their capital expenditures for AI infrastructure, with Microsoft planning to spend $88.2 billion in the 2025 fiscal year, followed by Google and Meta with substantial increases as well [3][4]

Core Viewpoint - The article discusses the performance of the Science and Technology Innovation ETF (科创ETF, 588050), highlighting its recent gains and the performance of its major holdings [1]. Group 1: ETF Performance - The Science and Technology Innovation ETF (588050) opened with a gain of 1.06%, priced at 1.146 yuan [1]. - Since its establishment on September 28, 2020, the ETF has recorded a return of -21.05%, while its return over the past month has been 10.56% [1]. Group 2: Major Holdings - Key stocks within the ETF include: - SMIC (中芯国际) up by 1.81% - Haiguang Information (海光信息) up by 0.74% - Cambricon (寒武纪) up by 2.88% - Lattice Semiconductor (澜起科技) up by 0.02% - Zhongwei Company (中微公司) up by 0.77% - Kingsoft Office (金山办公) up by 0.48% - United Imaging (联影医疗) up by 0.38% - Transsion Holdings (传音控股) up by 0.07% - Ninebot (九号公司) up by 0.10% - Chipone (芯原股份) up by 2.69% [1].

第一财经每日早间精选热点新闻，点击「听新闻」，一键收听。 【今日推荐】 特朗普：在俄罗斯问题上取得重大进展 【观国内】 国新办发表《2024年美国侵犯人权报告》 国务院新闻办公室17日发表《2024年美国侵犯人权报告》，揭示在权力与资本合谋之下，美式人权被异化为政治"秀场"上的道具和权力"赌场"中的筹码，背 离了人权的核心价值和本质要求。报告分为"序言""美式民主：金权游戏的狂欢""民生福祉：底层民众的挣扎""种族主义：少数族裔的枷锁""脆弱群体：妇女 儿童的无助""致命旅途：无证移民的悲歌""美式霸权：他国人权的梦魇""结语"等部分。 我国中东部大范围高温闷热天气持续发力 华南等地仍有强降雨 8月17日至18日，受南海热带低压和季风气流的共同影响，西南、华南等地的强降雨将持续发力，同时华北、东北地区还会迎来降雨和强对流天气的"组合 拳"。未来10天，随着副热带高压继续加强西伸北抬，高温闷热天气会向北扩展，高温核心区域的四川盆地、浙江等地最高气温可达40℃以上。 我国首个搭载气象雷达的海上升压站完成安装 8月16日，我国首个搭载气象雷达的海上升压站，在三峡江苏大丰800兆瓦海上风电项目现场完成安装，该设施将实 ...

Core Viewpoint - The company is actively leveraging artificial intelligence (AI) technology to enhance its medical imaging and radiation therapy capabilities, focusing on improving diagnostic efficiency and patient experience while navigating complex global trade environments [2][3][5]. AI Strategy and Applications - AI technology is becoming a key driver for innovation in medical imaging and radiation therapy, with hospitals increasingly favoring AI-enabled products for tasks such as lung nodule detection and brain hemorrhage screening [2][3]. - The company has developed several AI platforms across its product lines, including the uSense platform for CT, uAIFI for MR, and uExcel for molecular imaging, which enhance diagnostic accuracy and operational efficiency [5][11]. - Specific advancements include the uMRJupiter 5.0T MRI system, which improves imaging speed by 40% and enhances detection capabilities for small lesions, and the uMIPanvivo PET/CT system, which reduces full-body scan time to one minute [2][5]. Market Position and Global Strategy - The company has established a strong presence in the European market, with over 500 high-end medical devices serving more than half of EU member states, and is adapting its strategy in response to new EU procurement policies [2][3]. - The company aims to diversify its global supply chain and enhance local operations to mitigate risks associated with geopolitical factors, having set up subsidiaries in Poland and the Netherlands [2][3]. Financial Performance and Investment - The company reported fluctuations in operating cash flow due to macroeconomic factors and strategic investments, with R&D expenditures reaching 22.61 billion yuan, accounting for 21.95% of revenue [2][4]. - Despite short-term cash flow challenges, the company is focused on long-term value creation through innovation and global expansion, with a significant increase in overseas marketing and service teams [4][12]. Product Development and Innovation - The company is addressing common MRI challenges such as noise and scan duration through innovations like the QScan technology, which reduces noise levels by up to 97% and the ACS technology that cuts scan times by 80% [7][10]. - The introduction of the uMRUltra 3.0T MRI system and the uMROMEGA 3.0T system with advanced features aims to enhance patient comfort and diagnostic capabilities [8][10]. Shareholder Engagement and Dividends - The company has implemented a stable dividend policy, having distributed over 5.3 billion yuan since its IPO, and is committed to enhancing shareholder returns while balancing the need for reinvestment in high-tech medical equipment [12][14].

Core Viewpoint - The upcoming week will see 35 stocks in the A-share market facing the lifting of lock-up restrictions, with a total of 3.942 billion shares being released, amounting to a market value of approximately 99.964 billion yuan, which is a decrease of 56.93% compared to the previous week [1][2]. Summary by Category Stock Unlocking Details - Among the 35 stocks, the largest unlock market value will be from United Imaging Healthcare at over 29 billion yuan, followed by GeKong Microelectronics at over 16 billion yuan, and Hualan Biological Engineering at approximately 8.5 billion yuan [2][4]. - The unlocking dates for key stocks are as follows: United Imaging Healthcare on August 22 with 23.09 million shares, GeKong Microelectronics on August 18 with 105 million shares, and Hualan Biological Engineering on August 18 with 4.59 million shares [2][4]. Market Performance - As of August 15, the stock price changes since August for United Imaging Healthcare, GeKong Microelectronics, and Hualan Biological Engineering are -4.01%, +2.03%, and -2.11% respectively [3]. Unlocking Proportions - Six stocks will see their unlocking shares exceed 50% of their total share capital, including Hualan Biological Engineering (76.37%), GeKong Microelectronics (67.76%), and others, leading to significant increases in their circulating shares [8][9]. - The total number of stocks with a circulation increase of over 100% after unlocking will be eight, including notable increases for Hualan Biological Engineering and GeKong Microelectronics [8]. Detailed Stock Information - The detailed unlocking information for United Imaging Healthcare shows that its largest shareholders include United Imaging Technology Group and Shanghai Ying Sheng Investment Partnership, with a total unlocking of 16.76 million shares valued at approximately 21.44 billion yuan [6]. - For GeKong Microelectronics, the largest shareholder is Uni-sky Holding Limited, with an unlocking of 105 million shares valued at approximately 16.39 billion yuan [7].

Summary of Key Points Core Viewpoint - Next week, 35 stocks in the A-share market will face the unlocking of restricted shares, totaling 3.942 billion shares with a market value of approximately 99.964 billion yuan, a decrease of 56.93% compared to the previous week [1]. Company-Specific Summaries - **Unrestricted Shares and Market Value**: Among the 35 stocks, the largest market value of unlocked shares will be from United Imaging Healthcare at over 29 billion yuan, followed by GeKong Microelectronics at over 16 billion yuan, and Hualan Biological Engineering at approximately 8.5 billion yuan [2][4]. - **Unlock Dates and Share Counts**: United Imaging Healthcare will unlock 23.09 million shares on August 22, GeKong Microelectronics will unlock 1.05 billion shares on August 18, and Hualan Biological Engineering will unlock 4.59 million shares on August 18, all being original shareholders' restricted shares [2][4]. - **Stock Price Performance**: As of August 15, the stock price changes for the month are as follows: United Imaging Healthcare at -4.01%, GeKong Microelectronics at +2.03%, and Hualan Biological Engineering at -2.11% [3]. Unlocking Proportions and Impacts - **High Unlock Ratios**: Six stocks will have over 50% of their total shares unlocked, including Hualan Biological Engineering (76.37%), GeKong Microelectronics (40.38%), and others, leading to significant increases in their circulating shares [8][9]. - **Circulating Share Increases**: After the unlocking, the circulating shares of these six stocks will increase by 324.04%, 210.20%, and 207.77%, respectively, indicating a substantial impact on their liquidity [8][9]. Detailed Unlocking Information - **Top Ten Stocks by Unlock Value**: The top ten stocks by unlock value include United Imaging Healthcare, GeKong Microelectronics, and Hualan Biological Engineering, with respective unlock values of 29.54 billion yuan, 16.39 billion yuan, and 8.53 billion yuan [4][10]. - **Shareholder Details**: The major shareholders unlocking shares for United Imaging Healthcare include United Imaging Healthcare Technology Group and Shanghai Ying Sheng Investment Partnership, with the largest shareholder being United Imaging Healthcare Technology Group [6].